glp-1/gip/glucagon triple agonist Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research retatrutide mechanism glp-1 gip glucagon

Kreutzenberg, and G

Compared with active drugs, oral semaglutide was superior to empagliflozin in reducing total cholesterol and LDL [36] and was superior to sitagliptin in reducing total cholesterol, LDL, and TAGs [37, 41], but there was no significant difference when compared with another GLP-1 analogue (liraglutide) [38]

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial

June 2024 Update: The latest docket report from the Judicial Panel on Multidistrict Litigation (JPML) indicates that there are currently 101 lawsuits filed against the manufacturers of Ozempic and other GLP-1 agonist drugs in the Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation

But medications alone cant address every challenge PMOS brings

While current FDA approvals for semaglutide are limited to diabetes and weight management, the potential cognitive benefits may influence prescribing decisions for at-risk patients